Alpha memo: resveratrol exercise protocol mismatch

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Remove or substantially qualify the 'MAP reduction of ~45%' figure from the abstract, one-sentence alpha, and Why this is surprising section. Replace with language such as 'exercise training produced a 45% change in a cardiovascular parameter (truncated in source excerpt; exact endpoint unconfirmed)' and frame the signal qualitatively as blunting of an exercise-induced cardiovascular adaptation.
2. In the caveats/falsifiers, explicitly state that the precise cardiovascular endpoint and effect size cannot be verified from the truncated abstract excerpts, and that the blunting claim rests on the authors' framing rather than a confirmed numerical effect.
3. Consider softening the title from 'protocol mismatch' to something reflecting the actual signal: 'population-and-endpoint mismatch' or 'context-dependent interaction' to better match the receipts.

Major issues

• The MAP '~45% reduction' figure is not actually supported by the cited Receipt 2 abstract. The abstract states baseline MAP of 95.8 ± 2.2 mmHg and notes 'Exercise training led to a 45' before truncation. A 45% reduction in MAP would be physiologically implausible for an exercise intervention in normotensive men (~95 mmHg baseline), and the truncated text ('led to a 45') more likely refers to a different statistic (e.g., a relative % change in a flow-mediated dilation measure, or an absolute mmHg change). The memo should not report this number as confirmed.

Minor issues

• The abstract excerpt for Receipt 1 is also truncated, so feasibility claims should be characterized as 'per abstract excerpt, with safety/feasibility outcomes detailed elsewhere' rather than assumed clean.
• The DOI 10.1016/j.exger.2020.111111 is a placeholder-looking identifier (sequential 111111); worth verifying the actual PMID/DOI cross-reference.
• Title says 'resveratrol exercise protocol mismatch' but the memo's actual signal is a population/endpoint mismatch (functional limitations vs cardiovascular, feasibility vs attenuation), not strictly a protocol mismatch — minor title-claim alignment issue.

Reviewer note

The memo correctly identifies a real and interesting tension between two resveratrol+exercise RCTs: one (N=60, functionally limited older adults, 12 wk, 500/1000 mg) suggests feasibility, the other (N=27, healthy inactive aged men, 8 wk, 250 mg) suggests possible blunting of cardiovascular gains. The synthesis around population × dose × duration × baseline-health heterogeneity is well done. However, the specific '~45% MAP reduction' statistic is not verified by the cited excerpt (which truncates as 'Exercise training led to a 45' with no clear endpoint identification), and a 45% MAP reduction in normotensive men would be implausible. This requires the memo to either remove or appropriately hedge that figure. Sources are well-aligned to the thesis; Receipts are real and recent (2013, 2021). Title alignment is a minor issue — the signal is more about population/endpoint context-dependence than protocol mismatch per se. Recommend revise with bounded edits to address the unverified statistic.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis